Hans Jiro Becker
Overview
Explore the profile of Hans Jiro Becker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
122
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yogo T, Becker H, Kimura T, Iwano S, Kuchimaru T, Miyawaki A, et al.
Cell Rep
. 2025 Jan;
44(2):115241.
PMID: 39864058
Hematopoietic stem cells (HSCs) possess the capacity to regenerate the entire hematopoietic system. However, the precise HSC dynamics in the early post-transplantation phase remain an enigma. Clinically, the initial hematopoiesis...
2.
Sakurai M, Ishitsuka K, Becker H, Yamazaki S
Cancer Sci
. 2024 Jan;
115(3):698-705.
PMID: 38221718
Hematopoietic stem cells (HSCs) are a rare population of cells found in the bone marrow that play a critical role in lifelong hematopoiesis and the reconstitution of the hematopoietic system...
3.
Becker H, Yamazaki S
Exp Hematol
. 2023 Nov;
129:104133.
PMID: 38036097
CRISPR/Cas gene editing has transformed genetic research and is poised to drive the next generation of gene therapies targeting hematopoietic stem cells (HSCs). However, the installation of the "desired" edit...
4.
Becker H, Ishida R, Wilkinson A, Kimura T, Lee M, Coban C, et al.
Cell Stem Cell
. 2023 Jun;
30(7):987-1000.e8.
PMID: 37385251
Gene editing using engineered nucleases frequently produces unintended genetic lesions in hematopoietic stem cells (HSCs). Gene-edited HSC cultures thus contain heterogeneous populations, the majority of which either do not carry...
5.
Sakurai M, Ishitsuka K, Ito R, Wilkinson A, Kimura T, Mizutani E, et al.
Nature
. 2023 Feb;
615(7950):127-133.
PMID: 36813966
Haematopoietic stem cells (HSCs) are a rare cell type that reconstitute the entire blood and immune systems after transplantation and can be used as a curative cell therapy for a...
6.
Kayamori K, Nagai Y, Zhong C, Kaito S, Shinoda D, Koide S, et al.
Blood Adv
. 2021 Jan;
5(2):438-450.
PMID: 33496740
Dihydroorotate dehydrogenase (DHODH) catalyzes a rate-limiting step in de novo pyrimidine nucleotide synthesis. DHODH inhibition has recently been recognized as a potential new approach for treating acute myeloid leukemia (AML)...
7.
Takeda R, Asada S, Park S, Yokoyama A, Becker H, Kanai A, et al.
Blood
. 2020 Jun;
136(14):1670-1684.
PMID: 32492700
Additional sex combs-like 1 (ASXL1), an epigenetic modulator, is frequently mutated in myeloid neoplasms. Recent analyses of mutant ASXL1 conditional knockin (ASXL1-MT-KI) mice suggested that ASXL1-MT alone is insufficient for...
8.
Becker H, Kondo E, Shimabukuro-Vornhagen A, Theurich S, von Bergwelt-Baildon M
Eur J Haematol
. 2015 Nov;
97(2):166-74.
PMID: 26561366
Activated B cells have the capacity to present antigen and induce immune responses as potent antigen-presenting cells (APCs). As in other APCs, antigen presentation by B cells involves antigen internalization,...
9.
Weihrauch M, Richly H, von Bergwelt-Baildon M, Becker H, Schmidt M, Hacker U, et al.
Eur J Cancer
. 2014 Dec;
51(2):146-56.
PMID: 25480557
Purpose: This study was initiated to evaluate safety, toxicity, pharmacokinetics, and pharmacodynamics of treatment with MGN1703, a novel synthetic DNA-based toll-like receptor 9 (TLR9)-immunomodulator. Methods: The study consisted of an...